Completed
PHASE3
INTERVENTIONAL
NCT04184622
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Interventions
Name:
Tirzepatide
Type:
DRUG
Description:
Administered SC
Name:
Placebo
Type:
DRUG
Description:
Administered SC
Primary Outcomes
Measure:
Percent Change From Baseline in Body Weight (Primary Treatment Period)
TimeFrame:
Baseline, Week 72
Description:
Least Squares (LS) Mean was calculated using mixed-model repeated measures (MMRM) with baseline, analysis country, sex, prediabetes status at randomization, treatment, time, treatment\*time (Type III sum of squares) in the model.
Measure:
Percentage of Participants Who Achieve ≥5% Body Weight Reduction (Primary Treatment Period)
TimeFrame:
Week 72
Description:
Percentage of participants who achieve greater than or equal to( ≥) 5% body weight reduction.
Trial Information
NCT ID
NCT04184622
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025